Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin’s lymphoma patients

Boaz Nachmias*, Veronica Sandler, Elena Slyusarevsky, Galina Pogrebijski, Svetlana Kritchevsky, Dina Ben-Yehuda, Neta Goldschmidt, Moshe E. Gatt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Overt central nervous system (CNS) involvement in aggressive non-Hodgkin’s lymphoma (NHL) is rare at diagnosis. Much effort is put to identify risk factors for occult CNS involvement, and the risk assessment of CNS relapse. Prophylactic treatment carries risk of adverse events and its efficacy is not clear. Detection of cerebrospinal fluid molecular gene rearrangement (GRR) as a method to detect occult disease has been studied in acute leukemia and primary CNS lymphoma. To date, the capacity of a positive GRR in newly diagnosed NHL patients to predict CNS relapse has not been addressed. We retrospectively studied the prognostic value of GRR in cerebrospinal fluid samples of 148 newly diagnosed patients with high grade NHL. We demonstrate that positive GRR at diagnosis does not affect PFS or OS and did not predict CNS relapse. However, although numbers were small, repeated positive samples (≥ 2) correlated with a higher risk for CNS relapse (p = 0.048), possibly stressing the need for an aggressive preventive approach.

Original languageAmerican English
Pages (from-to)2561-2567
Number of pages7
JournalAnnals of Hematology
Issue number11
StatePublished - 1 Nov 2019
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.


  • CSF
  • Central nervous system (CNS)
  • Gene rearrangement
  • Non-Hodgkin lymphoma


Dive into the research topics of 'Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin’s lymphoma patients'. Together they form a unique fingerprint.

Cite this